Introduction: SLN is alternative to traditional colloidal carrier systems such as emulsion, liposome, and polymeric micro-and nanoparticles. They are highly biocompatibility, have low cytotoxicity, target-specific, scalability, prolonged drug release, and ease of production in industrial scale. Aims: The objective of the research is aimed at formulation of solid lipid nanoparticle (SLN) of dasatinib a tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia. Methodology: By investigating the relationship between design factors and experimental data using response surface methodology. A 33 Box-Behnken design was chosen using amount of glycerol monosterate (X1) the amount of poloxamer 407 (X2) and amount of tyloxopol (X3) level as independent factors. SLN prepared by hot emulsification / ultra-sonication method technique using glyceryl monostearate as the solid lipid, and poloxamer 407as the surfactant. The dependent variables include particle size (Y1), entrapment efficiency(Y2) and drug release after 12 h(Y3). Properties of SLN such as the morphology, FT-IR, particle size, zeta potential, entrapment efficiency and drug release behavior were investigated. Results: From the results DF10 was found to be optimized formulation, which shown that the nanoparticle designed are spherical in shape with a mean particle size of 112 nm with PI of 0.40 and zeta potential of __ampersandsignminus;25.6 mV. The in vitro release studies showed that more than 98.78% of drug was released from optimized SLN after 12 h, which is higher when compared with marketed formulation. The release kinetics of the optimized formulation followed zero Intriorder drug release and best fitted the Korsemeyer-peppas model. Conclusion: These results indicated that the dasatinib-loaded SLN formulation could potentially be exploited for the treatment of chronic myelogenous leukemia with controlled release manner.